Euler diagram indicating number and distribution of patients participating in each of the 6 clinical studies. In total, 360 unique patients with severe hemophilia A (FVIII activity level of <1%) who had previously received treatment with either plasma-derived or recombinant FVIII for ≥50 EDs (patients aged <6 years) or ≥150 EDs (patients aged ≥6 years) were enrolled in the 6 clinical studies NCT01599819, NCT01736475, NCT02210091, NCT01913405, NCT01945593, and NCT02585960, as described in Table 1. Some patients were enrolled in >1 study as indicated.